EGFR and cancer: Of the patients who received prior anti-cancer treatment, chemotherapy and chemo-immunotherapy were the most commonly used regimens (each used in 27.3%, n = 9/33), followed by tyrosine kinase inhibitors (18.2%, n = 6/33; including half of these patients who received EGFR tyrosine kinase inhibitors).